Biologically Active Cannabidiol Analogs
US-2021030708-A1 · Feb 4, 2021 · US
Biologically active cannabidiol analogs
US11337952B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11337952-B2 |
| Application number | US-202016896241-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 9, 2020 |
| Priority date | Jan 29, 2016 |
| Publication date | May 24, 2022 |
| Grant date | May 24, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R 1 or R 2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R 1 or R 2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R 1 or R 2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
First claim
Opening claim text (preview).
What we claim is: 1. A pharmaceutical composition for treatment of ocular diseases comprising a topical ophthalmic formulation wherein the formulation comprises a biologically active cannabidiol analog or a pharmaceutically acceptable salt thereof, wherein the analog is CBD-Di-Alaninate-Di-Hemisuccinate, CBD-Di-Valinate-Di-Hemisuccinate, CBD-Monovalinate-Di-Hemisuccinate, or CBD-Monovalinate-Mono-Hemisuccinate, having the formula wherein at least one of R 1 and R 2 is and the other of R 1 and R 2 is H, or both of R 1 and R 2 are: 2. The pharmaceutical composition of claim 1 wherein the analog is CBD-Divalinate-Di-Hemisuccinate, having the formula 3. The pharmaceutical composition of claim 1 wherein the analog is CBD-Monovalinate-Di-Hemisuccinate, having the formula 4. The pharmaceutical composition of claim 1 wherein the analog is CBD-Monovalinate-Mono-Hemisuccinate, having the formula wherein at least one of R 1 and R 2 is: and the other of R 1 and R 2 is H, or both of R 1 and R 2 are: 5. The pharmaceutical composition of claim 1 comprising the biologically active cannabidiol analog of claim 1 in a pharmaceutically acceptable carrier. 6. The pharmaceutical composition of claim 2 comprising the biologically active cannabidiol analog of claim 4 in a pharmaceutically acceptable carrier. 7. The pharmaceutical composition of claim 4 comprising the biologically active cannabidiol analog of claim 6 in a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
- A61K31/223Primary
of alpha-aminoacids · CPC title
o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol · CPC title
- A61K9/00Primary
Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)} · CPC title
Polycarboxylic acids · CPC title
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11337952B2 cover?
- Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R 1 or R 2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R 1 or R 2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R 1 or R 2 (in the case of the mono) is the residue of a dicar…
- Who is the assignee on this patent?
- Univ Mississippi
- What technology area does this patent fall under?
- Primary CPC classification A61K31/223. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).